| sofosbuvir/velpatasvir / Generic mfg. |
| Completed | 3 | 741 | Canada, US, Europe, RoW | SOF/VEL, Epclusa®, GS-7977/GS-5816, Placebo | Gilead Sciences | Hepatitis C Virus Infection | 06/15 | 09/15 | | |
|
|
ASTRAL-2, NCT02220998: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 12 Weeks in Adults With Chronic Genotype 2 HCV Infection |
|
|
| Completed | 3 | 269 | US | SOF/VEL, Epclusa®, GS-7977/GS-5816, SOF, Sovaldi®, GS-7977, PSI-7977, RBV | Gilead Sciences | Hepatitis C Virus Infection | 07/15 | 09/15 | | |
|
|
ASTRAL-4, NCT02201901: Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis |
|
|
| Completed | 3 | 268 | US | SOF/VEL, GS-7977/GS-5816, Epclusa®, RBV | Gilead Sciences | Hepatitis C Virus Infection | 08/15 | 11/15 | | |
|
ASTRAL-3, NCT02201953 / 2014-001682-27: Comparison of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks With Sofosbuvir and Ribavirin for 24 Weeks in Adults With Chronic Genotype 3 HCV Infection |
|
|
| Completed | 3 | 558 | Canada, US, Europe, RoW | SOF/VEL, Epclusa®, GS-7977/GS-5816, SOF, Sovaldi®, GS-7977, PSI-7977, RBV | Gilead Sciences | Hepatitis C Virus Infection | 09/15 | 12/15 | | |
|
| Completed | 3 | 111 | Canada, US, Europe, RoW | SOF/VEL, GS-7977/GS-5816, Epclusa® | Gilead Sciences | Hepatitis C Virus Infection | 03/16 | 06/16 | | |
NCT02480712: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection |
|
|
| Completed | 3 | 107 | US | SOF/VEL, GS-7977/GS-5816, Epclusa® | Gilead Sciences | Hepatitis C Virus Infection | 04/16 | 06/16 | | |
NCT02822794: Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen |
|
|
| Completed | 3 | 117 | Japan | SOF/VEL, GS-7977/GS-5816, Epclusa®, RBV, REBETOL® | Gilead Sciences | Hepatitis C Virus Infection | 06/17 | 08/17 | | |
| Completed | 3 | 119 | Europe, RoW | SOF/VEL, GS-7977/GS-5816, Epclusa® | Gilead Sciences | Hepatitis C Virus Infection | 06/17 | 09/17 | | |
GS-US-342-1518, NCT02671500: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV |
|
|
| Completed | 3 | 375 | RoW | SOF/VEL, GS-7977/GS-5816, Epclusa® | Gilead Sciences | Hepatitis C Virus Infection | 01/18 | 03/18 | | |
GS-US-342-1521, NCT03074331: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection |
|
|
| Completed | 3 | 130 | RoW | SOF/VEL, Epclusa®, GS-7977/GS-5816 | Gilead Sciences | Hepatitis C Virus Infection | 02/18 | 02/18 | | |
NCT02996682: Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis |
|
|
| Completed | 3 | 102 | Japan | SOF/VEL, Epclusa®, RBV, Rebetol® | Gilead Sciences | Hepatitis C Virus Infection | 02/18 | 05/18 | | |
NCT04112303: Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination for 12 Weeks in Adults With Chronic HCV Infection and Compensated Cirrhosis |
|
|
| Completed | 3 | 37 | Japan | SOF/VEL, GS-7977/5816, Epclusa® | Gilead Sciences | Hepatitis C Virus Infection | 03/21 | 06/21 | | |
NCT03891550: Micro-elimination of Hepatitis C Virus Infection in Uremics |
|
|
| Active, not recruiting | 3 | 135 | RoW | Epclusa | Kaohsiung Medical University Chung-Ho Memorial Hospital | Hepatitis C | 04/24 | 04/24 | | |
NCT02825212: Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia |
|
|
| Completed | 2/3 | 10 | US | Harvoni, Ledipasvir/Sofosbuvir, LDV/SOF FDC, Epclusa, Sofosbuvir/Velpatasvir | Icahn School of Medicine at Mount Sinai, Gilead Sciences | Hepatitis C, Cryoglobulinemia | 07/19 | 07/19 | | |
| Completed | 2/3 | 54 | US | Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Epclusa, Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET], Mavyret | Ohio State University | Kidney Transplant, Hepatitis C, HCV | 04/21 | 04/21 | | |
